Biospring Gmbh

BioSpring GmbH is one of the pioneers in the oligonucleotide CDMO industry, with a proven track record since 1997. BioSpring provides fully integrated manufacturing and analytical services for clinical (ICH Q7) and commercial oligonucleotide (ASOs, siRNAs, guide RNAs & more) programs. Dedicated project teams combine deep regulatory expertise with personalized support to guide programs from early clinical filings through full market authorization. cGMP-certified since 2007 and regularly FDA-inspected since 2016, this track record reflects a long-standing commitment to quality. Through global partnerships with leading biotech and pharmaceutical companies, we actively support clinical trials worldwide as well as nine commercial oligonucleotide products. Most recently, BioSpring will invest $150 million to build a new high-tech oligonucleotide manufacturing facility in Offenbach, Germany, our largest metric-ton capacity expansion to date. Trusted for high-quality we continue to be the partner of choice for advancing oligonucleotide therapies from bench to bedside. Privacy notice: Privacy notice for social media: